Update on tolterodine extended-release for treatment of overactive bladder

References

• Abrams P, Cardozo L, Fall M. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol. 2006;50(6):1306–1314.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C. The economic impact of overactive bladder syndrome in six Western countries. BJU Int. 2009;103(2):202–209.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: Results from the EPIC study. BJU Int. 2008;101(11):1388–1395.
   PubMed Web of Science ®Google Scholar
• Andersson KE. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol. 2004;3:46–53.
   PubMed Web of Science ®Google Scholar
• Abrams P, Freeman R, Anderström C, Mattiasson A. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol. 1998;81(6):801–810.
   PubMedGoogle Scholar
• van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A; Tolterodine Study Group. Tolterodine once-daily: Superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001;57(3): 414–421.
   PubMed Web of Science ®Google Scholar
• Novara G, Galfano A, Secco S, et al. A systematic review and metaanalysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54(4):740–763.
   PubMed Web of Science ®Google Scholar
• Freeman R, Hill S, Millard R, Slack M, Sutherst J. Reduced perception of urgency in treatment of overactive bladder with extended release tolterodine. Obstet Gynecol. 2003;102(3):605–611.
   PubMed Web of Science ®Google Scholar
• Khullar V, Hill S, Laval KU, Schiøtz HA, Jonas U, Versi E. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: A randomized, placebo-controlled trial. Urology. 2004;64(2):269–274.
   PubMed Web of Science ®Google Scholar
• Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology. 2006;67(4):731–736.
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Kreder K, MacDiarmid S, Carlsson M, Guan Z. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder. BJU Int. 2007;100(1):107–110.
   PubMed Web of Science ®Google Scholar
• Salvatore S, Serati M, Digesu GA, et al. Efficacy of tolterodine in relation to different urodynamic findings of detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(5):701–704.
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Kreder KJ, Pleil AM, Burgess SM, Reese PR. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care. 2002; 8 Suppl 19:S616–S630.
   Google Scholar
• Rogers R, Bachmann G, Jumadilova Z, et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(11):1551–1557.
   PubMed Web of Science ®Google Scholar
• Rogers RG, Omotosho T, Bachmann G, Sun F, Morrow JD. Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20(4):381–385.
   PubMed Web of Science ®Google Scholar
• Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006;18(4):CD003781.
   Google Scholar
• Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2005;20(3):CD005429.
   Google Scholar
• Urinary Incontinence. The management of urinary incontinence in women. National Institute for Health and Clinical Excellence, Oct 2006. Available at: http://www.nice.org.uk/nicemedia/live/10996/30281/30281.pdf. Accessed 2010 Sep 29.
   Google Scholar
• Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: The antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin. 2002;18(4):177–184.
   PubMed Web of Science ®Google Scholar
• Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial. Mayo Clin Proc. 2003;78(6):687–695.
   PubMed Web of Science ®Google Scholar
• Anderson RU, MacDiarmid S, Kell S, Barada JH, Serels S, Goldberg RP. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(5):502–511.
   PubMed Web of Science ®Google Scholar
• Chu FM, Dmochowski RR, Lama DJ, Anderson RU, Sand PK. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: A subanalysis of data from the OPERA trial. Am J Obstet Gynecol. 2005;192(6):1849–1854.
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62(2):237–242.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial. Eur Urol. 2005;48(3):464–470.
   PubMed Web of Science ®Google Scholar
• Junemann KP, Halaska M, Rittstein T, et al. Propiverine versus tolterodine: Efficacy and tolerability in patients with overactive bladder. Eur Urol. 2005;48(3):478–482.
   PubMed Web of Science ®Google Scholar
• Chapple C, van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52(4):1204–1212.
   PubMed Web of Science ®Google Scholar
• Chapple CR, van Kerrebroeck PE, Junemann KP, Wang JT, Brodsky M. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int. 2008;102(9):1128–1132.
   PubMed Web of Science ®Google Scholar
• Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: A head-to-head placebo-controlled trial. BJU Int. 2010;105(1):58–66.
   PubMed Web of Science ®Google Scholar
• Todorova A, vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol. 2001;41(6):636–644.
   PubMed Web of Science ®Google Scholar
• D’Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008;14(3):291–301.
   PubMed Web of Science ®Google Scholar
• Gopal M, Haynes K, Bellamy SL, Arya LA. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol. 2008;112(6):1311–1318.
   PubMed Web of Science ®Google Scholar
• Sears CL, Lewis C, Noel K, Albright TS, Fischer JR. Overactive bladder medication adherence when medication is free to patients. J Urol. 2010;183(3):1077–1081.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Nilvebrant L. Tolterodine: Selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers. Drugs R D. 2002;3(2):75–81.
   PubMedGoogle Scholar
• Stahl MM, Ekstrom B, Sparf B, Mattiasson A, Andersson KE. Urodynamic and other effects of tolterodine: A novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn. 1995;14(6):647–655.
   PubMed Web of Science ®Google Scholar
• Bharucha AE, Seide B, Guan Z, Andrews CN, Zinsmeister AR. Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects. Neurogastroenterol Motil. 2008;20(6):643–648.
   PubMed Web of Science ®Google Scholar
• Jewart RD, Green J, Lu CJ, Cellar J, Tune LE. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry. 2005;13(4):324–328.
   PubMed Web of Science ®Google Scholar
• Salvatore S, Serati M, Cardozo L, Uccella S, Bolis P. Cognitive dysfunction with tolterodine use. Äm J Obstet Gynecol. 2007;197(2):E8.
   PubMed Web of Science ®Google Scholar
• Olshansky B, Ebinger U, Brum J, Egermark M, Viegas A, Rekeda L. Differential pharmacological effects of antimuscarinic drugs on heart rate: A randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants <50 years. J Cardiovasc Pharmacol Ther. 2008;13(4):241–251.
   PubMed Web of Science ®Google Scholar
• Malhotra BK, Glue P, Sweeney K, Anziano R, Mancuso J, Wicker P. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther. 2007;81(3):377–385.
   PubMed Web of Science ®Google Scholar
• Schiffers M, Sauermann P, Schurch B, Mehnert U. The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects. World J Urol. 2010;28(5):651–656.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Thorpe A, Warner J, Sidhu M. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. BJU Int. 2010;106(4):506–514.
   PubMed Web of Science ®Google Scholar